Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19511160 | 0.81 | TDP1 (0.49) | TDP1ALDH1A1RAB9AKMT2AEGLN1 | |
| SCHEMBL4993186 | 0.81 | PDGFRB (0.42) | TDP1ALDH1A1L3MBTL1MAPK1POLB | |
| SCHEMBL20865688 | 0.76 | TDP1 (0.49) | TDP1ALDH1A1RAB9AKMT2AEGLN1 | |
| SCHEMBL7886556 | 0.75 | TDP1 (0.54) | TDP1ALDH1A1RAB9AKMT2ALMNA | |
| SCHEMBL2706463 | 0.75 | ALDH1A1 (0.61) | TDP1ALDH1A1RAB9AKMT2ALMNA | |
| SCHEMBL10359930 | 0.73 | TDP1 (0.57) | TDP1ALDH1A1RAB9AKMT2ALMNA | |
| SCHEMBL11758387 | 0.72 | DTYMK (0.44) | TDP1ALDH1A1CYP3A4TSHRBACE1 | |
| SCHEMBL428326 | 0.72 | GPR35 (0.42) | TDP1ALDH1A1LMNACYP3A4TSHR | |
| SCHEMBL15314942 | 0.72 | ALDH1A1 (0.50) | TDP1ALDH1A1RAB9AKMT2ALMNA | |
| SCHEMBL2014208 | 0.72 | TSHR (0.60) | TDP1ALDH1A1RAB9AKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| EP-2481739-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| EP-2481739-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | PLK2, PLK3, DMPK | TDP1 2733/4885ALDH1A1 1507/4885RAB9A 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.